- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02154477
Effect of Intranasal Insulin on LH Concentrations in Man
July 23, 2019 updated by: Texas Tech University Health Sciences Center
Over the last few years, studies have shown that men with type 2 diabetes sometimes develop a condition called hypogonadotrophic hypogonadism (HH).
People with this condition produce little or no sex hormones.
Obesity and metabolic syndrome are also associated with HH.
Research suggests that insulin in the brain may benefit the glands that release these hormones.
During this study, subjects will spray a small amount of insulin into their nose.This will increase insulin concentrations in the brain.
The purpose of this study is to find out the effect of one dose of intranasal insulin on release of LH (a sex hormone) in obese diabetic men with HH.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Studies over the last few years have clearly established that at least 25% of men with type 2 diabetes have subnormal free testosterone (T) concentrations in association with inappropriately low leutinizing hormone (LH) and FSH (follicle stimulating hormone) concentrations.
These patients thus suffer from hypogonadotrophic hypogonadism (HH).
Obesity and metabolic syndrome are also associated with HH.
Animal studies and in vitro data have shown that insulin action and insulin responsiveness in the brain are necessary for the maintenance of the functional integrity of the hypothalamo-hypophyseal-gonadal axis.
Insulin concentrations can be increased in the brain by delivering insulin intranasally with vianase device.
The aim of this project is to study the effect of one dose of intranasal insulin on release of LH in obese diabetic men with HH. 15 obese men with type 2 diabetes and low free T along with normal LH concentrations will be recruited for the study.
The study will be carried out at the clinical center of Texas Tech (Odessa campus).
There will be two study visits, each comprising of blood tests every 15 minutes over 6 hours.
40 IU of intranasal insulin or saline will be given after a baseline period of blood sampling of 2 hours.
Student's t-test will be used to compare the change in LH concentrations after intranasal saline or insulin.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Odessa, Texas, United States, 79763
- TTTUHSC-Permian Basin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Males age 18 to 75 years
- Obesity (BMI ≥30 kg/m2)
- Type 2 diabetes
- Hypogonadotropic hypogonadism defined as calculated free testosterone concentrations below 7 ng/dl along with normal or low LH concentrations
Exclusion Criteria:
- HbA1c>8.5%
- Use of preprandial insulin therapy
- Use of testosterone currently or in the past 4 months
- Use of over the counter health supplements which contain androgens
- Use of corticosteroids or narcotics in the past 3 months
- Coronary event or procedure(myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous twelve weeks
- Type I Diabetes
- Currently suffering from foot ulcer, significant periodontal disease or any other chronic infectious or inflammatory condition
- Hepatic disease (transaminase > 3 times normal) or cirrhosis
- Renal impairment (defined as glomerular filtration rate<30)
- HIV or Hepatitis C positive status
- Any other life-threatening, non-cardiac disease
- History of untreated severe obstructive sleep apnea(defined as apnea-hypopnea index ≥30)
- currently suffering from symptomatic depression, with or without treatment
- Use of an investigational agent or therapeutic regimen within 30 days of study
- Participation in any other concurrent clinical trial
- Pituitary tumor/damage/ other trophic hormone deficiency
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: diabetes
All patient will receive insulin at one visit and saline at another visit
|
insulin
saline
|
Active Comparator: control
All patient will receive insulin at one visit and saline at another visit
|
insulin
saline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LH
Time Frame: 4 hours
|
Luteinizing hormone (LH) concentrations after intranasal insulin as compared to placebo (intranasal saline).
This endpoint was measured in both arms
|
4 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sandeep Dhindsa, MD, TTUHSC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2014
Primary Completion (Actual)
December 1, 2017
Study Completion (Actual)
December 1, 2017
Study Registration Dates
First Submitted
May 30, 2014
First Submitted That Met QC Criteria
June 2, 2014
First Posted (Estimate)
June 3, 2014
Study Record Updates
Last Update Posted (Actual)
August 13, 2019
Last Update Submitted That Met QC Criteria
July 23, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- L14-075
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypogonadotropic Hypogonadism
-
Shanghai Jiao Tong University School of MedicineUnknownIdiopathic Hypogonadotropic Hypogonadism
-
Fudan UniversityRecruitingIdiopathic Hypogonadotropic Hypogonadism | Luteal Phase Support | Luteal Phase DeficiencyChina
-
Azienda Ospedaliero-Universitaria di ModenaRecruitingAcquired Hypogonadotropic HypogonadismItaly
-
Repros Therapeutics Inc.CompletedObesity | Acquired Hypogonadotropic HypogonadismUnited States
-
Massachusetts General HospitalTerminatedHypothalamic Amenorrhea | Idiopathic Hypogonadotropic HypogonadismUnited States
-
Ferring PharmaceuticalsCompletedPrimary Amenorrhea With Hypogonadotropic HypogonadismUnited States, Canada
-
Endo PharmaceuticalsCompletedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleUnited States
-
Rigshospitalet, DenmarkTerminatedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleDenmark
-
Amneal Pharmaceuticals, LLCPhase One Solutions, Inc.CompletedHypogonadotropic Hypogonadism | Primary HypogonadismUnited States
-
Huashan HospitalRecruitingHypogonadotropic HypogonadismChina
Clinical Trials on intranasal insulin
-
Michigan State UniversityCompletedExercise | InsulinUnited States
-
Wake Forest University Health SciencesCompleted
-
University Health Network, TorontoCompleted
-
University of BirminghamQueen Elizabeth Hospital NHS Foundation TrustCompleted
-
Johns Hopkins UniversityTerminatedHIV Dementia | HIV-Associated Cognitive Motor ComplexUnited States
-
University Health Network, TorontoCompletedInsulin Resistance, DiabetesCanada
-
Centre for Addiction and Mental HealthRecruitingDepression | Major Depressive DisorderCanada
-
HealthPartners InstituteJuvenile Diabetes Research Foundation; International Diabetes Center at Park...TerminatedType1diabetesUnited States
-
Rutgers, The State University of New JerseyAlzheimer's AssociationRecruitingMetabolic Syndrome | Alzheimer Disease | Mild Cognitive ImpairmentIsrael
-
Virginia Polytechnic Institute and State UniversityCompletedHuman Memory | Intranasal Insulin